OBJECTIVE: To analyze insulin resistance (IR) and determine the need for a 2-hour oral glucose tolerance test (OGTT) for the identification of IR and impaired glucose tolerance (IGT) in lean nondiabetic women with polycystic ovary syndrome (PCOS). METHODS: This was a cross-sectional analysis of treatment-naive women with PCOS who enrolled in a university-based clinical trial. Nondiabetic women with PCOS based on the Eunice Kennedy Shriven National Institute of Child Health and Human Development (NICHD) definition, aged 18-43 years and weighing ≤113 kg, were evaluated. Glucose and insulin levels were assessed at times 0, 30, 60, 90, and 120 minutes after a 75-g glucose load. Lean was defined as body mass index (BMI) <25 kg/m(2). Multiple linear regression was performed. RESULTS: A cohort of 78 women was studied. The prevalence of IR was 0% among lean women vs. 21% among nonlean subjects based on fasting insulin I(0) and 40%-68% based on two different homeostatic model assessment (HOMA) cutoff points (p < 0.005). All women with IR had a BMI ≥ 28. Controlling for age and race, BMI explained over 57% of the variation in insulin fasting (I(o)), glucose fasting/Io (G(o)/I(o)), the qualitative insulin sensitivity check index (QUICKI), and HOMA and was a highly significant predictor of these outcomes (p < 0.0001). Only 1 of 31 (3%) of the lean PCOS women had IGT based on a 2-hour OGTT, and no lean subjects had IGT based on their fasting blood glucose. CONCLUSIONS: Diabetes mellitus, IGT, and IR are far less common in young lean women with PCOS compared with obese women with PCOS. These data imply that it is unnecessary to routinely perform either IR testing or 2-hour OGTT in lean women with PCOS; however, greater subject accumulation is needed to determine if OGTT is necessary in lean women with PCOS. BMI is highly predictive of both insulin and glucose levels in women with PCOS.
RCT Entities:
OBJECTIVE: To analyze insulin resistance (IR) and determine the need for a 2-hour oral glucose tolerance test (OGTT) for the identification of IR and impaired glucose tolerance (IGT) in lean nondiabeticwomen with polycystic ovary syndrome (PCOS). METHODS: This was a cross-sectional analysis of treatment-naive women with PCOS who enrolled in a university-based clinical trial. Nondiabeticwomen with PCOS based on the Eunice Kennedy Shriven National Institute of Child Health and Human Development (NICHD) definition, aged 18-43 years and weighing ≤113 kg, were evaluated. Glucose and insulin levels were assessed at times 0, 30, 60, 90, and 120 minutes after a 75-g glucose load. Lean was defined as body mass index (BMI) <25 kg/m(2). Multiple linear regression was performed. RESULTS: A cohort of 78 women was studied. The prevalence of IR was 0% among lean women vs. 21% among nonlean subjects based on fasting insulin I(0) and 40%-68% based on two different homeostatic model assessment (HOMA) cutoff points (p < 0.005). All women with IR had a BMI ≥ 28. Controlling for age and race, BMI explained over 57% of the variation in insulin fasting (I(o)), glucose fasting/Io (G(o)/I(o)), the qualitative insulin sensitivity check index (QUICKI), and HOMA and was a highly significant predictor of these outcomes (p < 0.0001). Only 1 of 31 (3%) of the lean PCOSwomen had IGT based on a 2-hour OGTT, and no lean subjects had IGT based on their fasting blood glucose. CONCLUSIONS:Diabetes mellitus, IGT, and IR are far less common in young lean women with PCOS compared with obesewomen with PCOS. These data imply that it is unnecessary to routinely perform either IR testing or 2-hour OGTT in lean women with PCOS; however, greater subject accumulation is needed to determine if OGTT is necessary in lean women with PCOS. BMI is highly predictive of both insulin and glucose levels in women with PCOS.
Authors: M Gutt; C L Davis; S B Spitzer; M M Llabre; M Kumar; E M Czarnecki; N Schneiderman; J S Skyler; J B Marks Journal: Diabetes Res Clin Pract Date: 2000-03 Impact factor: 5.602
Authors: M Asunción; R M Calvo; J L San Millán; J Sancho; S Avila; H F Escobar-Morreale Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: Brett R Ely; Zachary S Clayton; Carrie E McCurdy; Joshua Pfeiffer; Karen Wiedenfeld Needham; Lindan N Comrada; Christopher T Minson Journal: Am J Physiol Endocrinol Metab Date: 2019-05-28 Impact factor: 4.310
Authors: Yong Zhang; Jie Sun; Feng Li; Tristan R Grogan; Jose L Vergara; QingXian Luan; Moon-Soo Park; David Chia; David Elashoff; Kaumudi J Joshipura; David T W Wong Journal: Diabetes Res Clin Pract Date: 2017-07-19 Impact factor: 5.602